An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Spectrum Pharmaceuticals Announces Poster Presentation at the Upcoming AACR Annual Meeting
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Spectrum Pharmaceuticals (NASDAQ: SPPI) announced the acceptance of an abstract for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 8-13, 2022 in New Orleans. The presentation, titled Predictive ability of circulating tumor DNA by Guardant360 in poziotinib-treated patients, will occur on April 12, 2022, showcasing data on NSCLC patients with HER2 exon 20 mutations. Additional details will be available on Spectrum's website post-presentation.
Positive
Acceptance of poster presentation at AACR Annual Meeting, enhancing visibility in oncology research.
Focus on novel therapies highlights Spectrum's commitment to addressing unmet medical needs.
Negative
No new clinical results or data released; reliance on previously published findings may limit impact.
Forward-looking statements include risks related to drug safety and efficacy, which could hinder investor confidence.
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced abstract acceptance with a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in New Orleans from April 8-13, 2022.
Session title and information for the poster is listed below and is now available on the AACR online itinerary planner.
Predictive ability of circulating tumor DNA by Guardant360 in poziotinib-treated patients with NSCLC harboring HER2 exon 20 insertion mutations
Session Title: PO.CL11.03 - Cell-Free DNA 2
Session Date and Time: Tuesday, April 12, 2022; 1:30 PM - 5:00 PM CT Location: New Orleans Convention Center, Section 31
Abstract / Poster: 3400 / 6
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.
Notice Regarding Forward-looking Statements
This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum’s business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.
What is the poster presentation by Spectrum Pharmaceuticals at the AACR Annual Meeting?
Spectrum Pharmaceuticals will present a poster on the predictive ability of circulating tumor DNA in poziotinib-treated patients at the AACR Annual Meeting.
When is the AACR Annual Meeting where Spectrum Pharmaceuticals will present?
The AACR Annual Meeting will take place from April 8-13, 2022, in New Orleans.
What session will Spectrum Pharmaceuticals present at the AACR Annual Meeting?
Spectrum Pharmaceuticals will present in the session titled 'Cell-Free DNA 2' on April 12, 2022.
What is the significance of the poster presentation for Spectrum Pharmaceuticals?
The acceptance of the poster presentation at a major conference like AACR enhances Spectrum's visibility in the oncology field.
What potential risks did Spectrum Pharmaceuticals mention regarding future performance?
Spectrum noted risks including the possibility of drug candidates not proving safe or effective, which could affect future performance.
